Shore Capital Partners Announces Closing of Fund I
May 30, 2014
June 5, 2014 ‐ Shore Capital Partners, a Chicago‐based healthcare focused private equity firm, announced today that it has successfully completed fundraising for Shore Capital Partners Fund I (“Fund I”), which was substantially oversubscribed and closed with $112.5 million of committed capital.
Fund I will continue the successful investment strategy employed by the firm’s predecessor investment vehicles and invest primarily in control buyouts, focusing on microcap healthcare businesses with $1 to $5 million in EBITDA. Shore targets equity commitments of $10 ‐ $15 million per platform. Investors in Fund I include leading pension funds, financial institutions, fund of funds and family offices.
“We are very pleased with the reception Shore Capital Partners Fund I received from such a highly respected group of institutional investors,” said Justin Ishbia, Founder and Managing Partner of Shore Capital Partners. “This is an important milestone for Shore and we believe the interest shown by investors validates our strategy to invest in microcap healthcare companies that can benefit from our operational and financial support.”
Shore has assembled an experienced team to manage the Fund and actively assist portfolio companies. Shore’s principals have been investing together since 2009, completing 14 acquisitions across five platforms. Prior to founding Shore, Justin Ishbia worked at Valor Equity Partners and previously was an attorney in the private equity group at Kirkland Ellis. Ryan Kelley worked as an investment professional at Water Street Healthcare Partners and previously in the healthcare investment banking group at Bank of America. Michael Cooper was an investment professional at Wind Point Partners and previously at UBS Investment Bank. John Hennegan worked at Henry Crown & Company and previously at Citigroup in their investment bank. Don Pierce joined the team in the fall of 2013 from Baxter International and worked previously at RoundTable Healthcare Partners and UBS Investment Bank. Further, Shore has cultivated a strong roster of experienced healthcare Operating Partners to assist in deal sourcing, due diligence, and portfolio company management.
Shore invests in companies with strong growth potential in favorable niche segments in healthcare services, medical products and consumer‐directed healthcare, where the team can help transform the company from a local leader to a regional player.